

**Amendments to the Claims**

**This listing of claims will replace all prior versions and listing of claims in the application.**

Claims 1-2 (Canceled)

3. (Original) The salt (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen (2R,3R)-tartrate monohydrate.

4. (Previously presented) The salt according to claim 3 in crystalline form.

5. (Previously presented) A pharmaceutical formulation containing, as active ingredient, the salt according to claim 3 or 4 in association with a suitable diluent, excipient or an inert carrier.

Claims 6-11 (Canceled)

12. (Currently amended) A method for the ~~[prevention or the]~~ treatment of **a condition selected from the group consisting of depression and anxiety** ~~[CNS disorders and related medical disturbances]~~ comprising administration, to a host in need of such treatment, an effective amount of the salt according to claim 3 or 4.

13. (Canceled)

14. (Currently amended) **The [A]** method according to claim **12, wherein the condition is** ~~[+3 for the prevention or the treatment of]~~ depression.

15. (Currently amended) **The** [A] method according to claim **12, wherein the condition is** [13 ~~for the prevention or the treatment of~~] anxiety.

16. (Currently amended) A process of making the salt as defined in claim 3 or 4 which comprises the following consecutive steps:

- i) dissolving (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide in an **organic** [~~appropriate~~] solvent, optionally by heating,
  - ii) adding (2R, 3R)-tartaric acid dissolved in an [~~appropriate~~] aqueous organic solvent or non-aqueous organic solvent,
  - iii) allowing the solution obtained to stand cold to crystallize,
  - iv) optionally recrystallizing in an [~~appropriate~~] aqueous organic solvent, if a non-aqueous organic solvent is used in step ii),
- to obtain the salt defined in any one of claims 3 or 4.

17. (Currently amended) A process of making the salt as defined in claims 3 to 4 which comprises [~~a final step of~~] recrystallizing (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-benzopyran-5-carboxamide hydrogen (2R, 3R)-tartrate in an [~~appropriate~~] aqueous organic solvent.

18. (Currently amended). **The** [A] process according to claim 16 **or 17**, wherein the aqueous organic solvent is aqueous acetone.

Claims 19-20 (Canceled)

21. (Currently amended) The [A] pharmaceutical formulation according to claim 5, wherein the pharmaceutical formulation is an oral dosage form ~~[for oral administration]~~.

Claims 22-43 (Cancel)

44. (Currently amended) The pharmaceutical formulation according to claim 5 further comprising [Claim 42] a lubricant.

Claims 45-54 (Cancelled)